Ann: Update - AnteoTech signs manufacturing contract with Operon, page-178

Hey@Stockcount - I know why you want: "An indication of earnings/profit per test, in AUD, would be soooo useful. " - ie to reduce some uncertainties that shareholders may have.
But I am very very keen that ADO DOES NOT tell us (and hence the world) how much profit it will make per test nor how much it will sell each one for. This should be commercial-in-confidence to ADO management so that they can negotiate as good a price as they can get for each jurisdiction and customer.
eg if it were the case that ADO could manufacture tests in bulk for 50c each and possibly sell them for $10 each (NOTE: off-the-wall numbers for illustrative purposes only - no basis in known fact!) this should be known only to select ADO management (and BOD) as we don't want the cost base to be a starting point for price negotiation.
I am happy to wait to the 2021 (Financial) Annual Report to be able to try to do the back analysis to estimate cost price and sale price.
Of course we will get some indicators in earlier quarterlies and any major contract announcements.
Be patient mate; it is in our interests to be so!